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Mutations in CBL occur frequently in juvenile myelomonocytic
leukemia
Abstract
Juvenile myelomonocytic leukemia is an aggressive myeloproliferative disorder characterized by
malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated
progeny. Seventy-five percent of patients harbor mutations in the NF1, NRAS, KRAS, or PTPN11
genes, which encode components of Ras signaling networks. Using single nucleotide polymorphism
arrays, we identified a region of 11q isodisomy that contains the CBL gene in several JMML samples,
and subsequently identified CBL mutations in 27 of 159 JMML samples. Thirteen of these mutations
alter codon Y371. In this report, we also demonstrate that CBL and RAS/PTPN11 mutations were
mutually exclusive in these patients. Moreover, the exclusivity of CBL mutations with respect to other
Ras pathway-associated mutations indicates that CBL may have a role in deregulating this key pathway
in JMML.
doi:10.1182/blood-2009-01-198416 
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MYELOID NEOPLASIA
Brief report
Mutations in CBL occur frequently in juvenile myelomonocytic leukemia
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Juvenile myelomonocytic leukemia is an
aggressive myeloproliferative disorder char-
acterized by malignant transformation in
the hematopoietic stem cell compartment
with proliferation of differentiated progeny.
Seventy-five percent of patients harbor mu-
tations in the NF1, NRAS, KRAS, or PTPN11
genes, which encode components of Ras
signaling networks. Using single nucleotide
polymorphism arrays, we identified a region
of 11q isodisomy that contains the CBL
gene in several JMML samples, and subse-
quently identified CBL mutations in 27 of
159 JMML samples. Thirteen of these muta-
tions alter codon Y371. In this report, we
also demonstrate that CBL and RAS/PTPN11
mutations were mutually exclusive in these
patients. Moreover, the exclusivity of CBL
mutations with respect to other Ras
pathway-associatedmutations indicates that
CBL may have a role in deregulating this
key pathway in JMML. (Blood. 2009;114:
1859-1863)
Introduction
Juvenile myelomonocytic leukemia (JMML) is an aggressive
clonal myeloproliferative disorder (MPD) of young children.1,2
Extensive molecular data implicate deregulated Ras signaling as a
key initiating event in JMML, with 60% of patients harboring
somatic PTPN11, NRAS, or KRAS mutations and another 10% to
15% of cases arising in children with neurofibromatosis type 1
(NF1) and/or showing somatic inactivation of the NF1 tumor
suppressor gene.3,4 Chronic myelomonocytic leukemia (CMML)
shares clinical and laboratory features with JMML, including a
high frequency of RAS mutations and a hypersensitive pattern of
granulocyte-macrophage colony-forming unit growth (CFU-GM)
in response to granulocyte-macrophage colony-stimulating factor
(GM-CSF).5-8 Moreover, phosphoflow cytometric analysis of
CD38dim/CD14/CD33 cells from JMML and CMML patients
recently demonstrated a distinctive pattern of STAT5 hyperphospho-
rylation in response to low doses of GM-CSF.9
Advances in detecting DNA copy number alterations and
acquired uniparental isodisomy (UPD) with single nucleotide
polymorphism (SNP) arrays have proven fruitful for discovering
mutations in other hematologic malignancies.10,11 To determine
whether regions of copy-neutral loss of heterozygosity (LOH)
indicative of acquired UPD existed in JMML, we performed
Affymetrix SNP 6.0 array analysis on samples from 27 JMML
patients with and without known PTPN11, RAS, or NF1 abnormali-
ties. We identified a region of 11q UPD in 5 of these cases, which
includes the CBL gene. Importantly, recent reports uncovered
acquired 11q copy-neutral LOH in related MPDs, and molecular
analysis identified CBL mutations in these cases.10,11 Furthermore,
a few CBL mutations had been reported previously in myeloid
malignancies.12-14 Based on these observations, we investigated
CBL in these 5 JMML patients with 11q copy-neutral LOH and
detected homozygous mutations in all cases. We then sequenced
diagnostic samples from 154 additional JMML patients assembled
from a large international cohort and identified 22 more with CBL
mutations. We also analyzed a series of 44 patients with CMML
who were treated at the M. D. Anderson Cancer Center for mutations
and detected several lesions in CBL.
Methods
Patient samples and DNA extraction
All patients or their guardians provided informed consent for these studies
according to the Declaration of Helsinki, and the experimental procedures
were reviewed and approved by institutional review committees at each
participating center. CMML patients were diagnosed and treated at M. D.
Anderson Cancer Center. Genomic DNA was isolated using PureGene
reagents (QIAGEN). A clinical history of NF1 was available for some, but
not all, patients. DNA from 40 anonymous, normal controls was also
analyzed.
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SNP array analysis
A total of 500 ng sample DNA was analyzed using Affymetrix 6.0 SNP arrays as
previously described.15-17 Extraction and summarization of SNP/CNV probe
hybridization intensities from CEL files were performed in dChip,18 and
normalization was performed using a “reference normalization” algorithm that
uses only probes from chromosomes known or predicted to be diploid to guide
array normalization.19 Additional details on the bioinformatic and statistical
analyses are included in supplemental data (available on the Blood website; see
the Supplemental Materials link at the top of the online article).
Mutational screening, progenitor colony, and phosphoflow
studies
All JMML and CMML patients had mutational screening for PTPN11,
NRAS, and KRAS performed as previously described.20-22 Polymerase chain
reaction amplification of CBL exons 8 and 9 was performed using primers
and conditions listed in supplemental Table 1. Polymerase chain reaction
products were visualized, purified, and sequenced according to standard
methodologies. CFU-GM colonies were grown according to previously
published methods.23
Statistical methods
The 2 test was used to examine the statistical significance of a relationship
between categorical variables. Because a normal distribution cannot be assumed,
median values and ranges were reported and nonparametric statistics were used
to test for differences in continuous variables for different subgroups (Kruskal-
Wallis test with subsequent posthoc Mann-Whitney U test). All P values were
2-sided, and values .05 were considered statistically significant. P values .1
were reported as nonsignificant, whereas those between 0.05 and 0.1 were
reported in detail. No adjustment of the -level to account for multiple testing
was performed because of the explorative nature of the statistical analysis and the
limited patient numbers available with clinical data.
Results and discussion
We analyzed 27 JMML samples enriched for patients without
known Ras pathway mutations for regions of copy-neutral LOH
and detected 11q UPD in 5 cases (Figure 1A, supplemental Figure
1). Based on recent reports of CBL mutations in patients with other
myeloid malignancies, we sequenced exons 8 and 9 of CBL in 26 of
27 of the patients who had SNP arrays performed (there was 1 pa-
tient without DNA available for sequencing, but this patient did not
exhibit 11q UPD) and in an additional 133 JMML samples.10-14
CBL sequencing data revealed 25 homozygous and 2 heterozygous
mutations (Figure 1C; Table 1) located throughout the linker and
RING finger domain, with the predominantly affected codon in
Figure 1. Identification of acquired isodisomy of 11q in JMML and CBL mutations. (A) Chromosome 11 loss-of-heterozygosity (LOH) data and copy number heatmaps
and plots are shown for 5 representative patients with homozygous CBL mutations, and demonstrate acquired copy-neutral LOH involving CBL for each patient. The region of
LOH (blue) in HM1993 is smaller than in the other cases shown but contains the CBL locus. The copy number heatmap generated by dChip is shown where pink represents a
diploid copy number, whereas areas of white and red represent loss and gain, respectively. The absence of white and red supports a copy neutral event. This is also
represented in the panel on the right where a diploid copy number is represented by the red vertical line, whereas gains and losses are traced in blue; no copy number
alterations on chromosome 11 were identified, indicating copy-neutral LOH. (B) Schematic of CBL with expansion of codons in exon 8. Highlighted in red are the residues in
exon 8 where missense mutations were identified in JMML and CMML. *Boundary of the linker and RING finger domains. Listed below are the codon numbers.
(C) Representative electropherograms from a normal control, the heterozygous mutation from the cord blood sample of HM1854, and the homozygous mutation at diagnosis.
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JMML being the tyrosine residue at position 371 (Y371; Figure 1C;
Table 1). No mutations were identified in 40 normal controls.
One patient who was diagnosed at 7 months of age (HM1854)
had an umbilical cord blood sample available for genotyping
(Figure 1C). Interestingly, DNA isolated from mononuclear cells at
diagnosis demonstrated a homozygous Y371H, whereas DNA
isolated from her cord blood demonstrated a heterozygous muta-
tion (Figure 1C). Similarly, SNP analysis of the diagnostic sample
revealed 11q isodisomy which was absent in the cord blood sample
(supplemental Figure 1). DNA extracted from hypersensitive CFU-GM
colonies plucked from cells propagated at diagnosis revealed that 10 of
16 colonies harbored homozygous lesions, whereas 6 were heterozy-
gous. Furthermore, an aliquot of cord blood was defrosted and
plated on complete methylcellulose, and a spectrum of colony-
forming unit–granulocyte, erythrocyte, monocyte/macrophage,
megakaryocyte and CFU-GM colonies were genotyped, with
almost all colonies demonstrating the heterozygous CBL mutation.
In a second patient (HM1658), an Epstein-Barr virus–
transformed cell line also harbored the identical homozygous
Y371H alteration seen in DNA from diagnosis. However, previous
data suggest that B cells are only rarely involved in the JMML
clone.24 Hypersensitive CFU-GM colonies picked at diagnosis
were largely homozygous for the CBL mutation (9 of 13 tested), but
the rest were heterozygous. Finally, in a third patient (HM1993),
DNA isolated from the buccal mucosa demonstrated a heterozy-
gous lesion, whereas the majority of CFU-GM colonies again
demonstrated homozygous mutations. Together, these data support
the hypothesis that reduplication of an inherited CBL mutation in a
pluripotent hematopoietic stem cell confers a selective advantage
for the homozygous state and also raise the possibility of germline
lesions in some patients with CBL mutations.
Consistent with other reports, we also detected CBL mutations
in 5 of 44 CMML samples (supplemental Table 2).10,11 None of the
specimens in this cohort with a RAS mutation (n  15) also had a
CBL mutation. However, 1 CMML patient had a mutation in both
JAK2 (V617F) and CBL. In contrast to JMML, we and others found
no Y371 alterations in CMML.10,11
We specifically assessed the frequency of CBL mutations in a
subset of 68 JMML cases without mutations in RAS or PTPN11.
Forty-five of these patients had no clinical evidence of NF1, and the
NF1 status was unknown in the other 23. We identified 27 CBL
mutations (39.7%). These data demonstrate CBL mutations in 10%
to 15% of JMML patients overall, which is similar to the frequency
of NF1 mutations. Importantly, we did not detect any CBL
mutations in 91 JMML samples with known mutations in RAS or
PTPN11. The difference in the frequency of CBL mutations in
JMML patients without mutations in either RAS, PTPN11, or NF1
(27 of 68) versus those with a known RAS or PTPN11 mutation
(0 of 91) was highly significant (Fisher exact test, P  .001).
We also compared the clinical features at diagnosis of patients
with CBL mutations vs those with an RAS, PTPN11, or no known
mutation (Table 2) and found that there was a tendency for
CBL-mutated patients to present at a younger age (P  .09),
although this was not statistically significant. Interestingly, there
were no cases of monosomy 7 in the CBL group; however, this was
also not statistically significant. Although there were also no
significant differences in overall survival among the mutation
groups, our sample size is not sufficiently large enough to detect
modest differences. Future prospective analyses of genotype/
phenotype correlations will therefore be necessary to extend
these findings.
In previous studies of phospho-signaling networks in JMML,
we evaluated 10 specimens from patients with known KRAS,
NRAS, PTPN11, or NF1 mutations and 4 without a known Ras
pathway lesion.9 DNA sequence analysis revealed CBL mutations
in 3 of these 4 patients. These 3 cases exhibited a similar pattern of
CFU-GM hypersensitivity in methylcellulose cultures and ex-
pressed high levels of pSTAT5 in response to low doses of
GM-CSF, similar to other JMML patients with somatic mutations
in RAS/PTPN11 or NF1 (the 3 cases with CBL mutations are
HM1661, 1854, and 1993).10
c-Cbl primarily functions as an E3 ubiquitin ligase and is
responsible for the intracellular transport and degradation of a large
number of receptor tyrosine kinases but also retains important
adaptor functions.25,26 Approximately 150 proteins associate with
or are regulated by c-Cbl.25 Among these proteins is Grb2, an
adaptor molecule that binds to c-Cbl and prevents it from binding
to SOS, a known guanine nucleotide exchange factor for Ras.27
CBL mutations reported in myeloid malignancies uniformly affect
either the linker region or the RING finger domain.10,12-14 Loss of
ubiquitination of activated receptor tyrosine kinases is thought to
contribute to the transforming potential of leukemia-associated
mutant Cbl proteins.14 Mutations that affect Y371 are rare in acute
myeloid leukemia28; however, expressing this mutant Cbl protein
with Flt3 in BaF3 cells induced cytokine-independent growth and
survival. Mutations in Y368 or Y371 could confer substantial
structural changes to the TKB domain that could ultimately affect
binding partners with different consequences.29 For example,
Y371F abolishes E3 ligase activity, whereas substitution to glu-
tamic acid confers constitutive activation.30,31 In addition, Y371
mediates binding of c-Cbl to the p85 regulatory subunit of PI3
kinase,32 and the Y371F abolishes this interaction.
The identification of homozygous CBL mutations in JMML
suggests that CBL is a new tumor suppressor gene. Cells from these
patients display identical GM-CSF hypersensitivity and pSTAT5
signaling as other known Ras pathway mutations. Moreover, the
known molecular genetic and biochemical features of JMML
and our data showing that CBL, PTPN11, KRAS, and NRAS are
mutually exclusive imply that leukemia-associated CBL mutations
result in hyperactive Ras. These effects of c-Cbl could be mediated
by failure of the mutant protein to efficiently target one or more
cytokine receptors for degradation by ubiquitination by an alterna-
tive biochemical mechanism. Along these lines, it is of interest that
Y371 is a “hot spot” for CBL mutations in JMML—that it is rarely
mutated in other myeloid malignancies, and that the majority of the
mutations detected are missense substitutions or in-frame deletions
resulting in a translated protein that may retain some function.
Table 1. CBL mutations detected in 27 JMML patients
Location Nucleotide change Amino acid change No. of patients
Intron 7 1096–1GC* Splice site 1
Exon 8 1111TC* 371 TyrHis 10
1111TG* 371 TyrAsp 2
1112AG* 371 TyrCys 1
1139TC* 380 LeuPro 1
1141TC* 381 CysArg 1
1150TC* 384 CysArg 4
1186TC* 396 CysArg 1
1190 del99bp Deletion 1
1210 TC* 404 CysArg 1
1222 TC* 408 TrpArg 1
Intron 8 12274CT Splice site 1
1228–2AG* Splice site 1
Exon 9 1244GT* 415 GlyVal 1
*Homozygous mutation.
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Further work will be necessary to unravel the biochemical
effects of these mutants on Ras networks and on other growth
control pathways.
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Table 2. Clinical characteristics of patients with CBL, PTPN11, RAS, or no mutation
Clinical characteristic CBL PTPN11 RAS No mutation P
Median age, y (range) 1.1 (0.1-3.6) 2.8 (0.4-5.7) 1.2 (0.01-6.0) 2.6 (0.1-12.2) .09
Sex
Male, n (%) 12 (63) 12 (60) 18 (82) 16 (76)
Female, n (%) 7 8 4 5 NS
WBC, 106/L
Less than 50 000, n (%) 15 (79) 15 (75) 13 (62) 16 (76)
More than or equal to 50 000, n (%) 4 (21) 5 (25) 8 (38) 5 (24) NS
Median monocytes, 106/L (range) 5320 (1380-38 840) 6040 (1690-20 390) 5040 (1030-28 350) 3140 (1170-50 100) NS
Hemoglobin, g/dL
Less than 8.0 g/dL, n (%) 5 (26) 3 (15) 6 (29) 6 (29)
More than 8.0 g/dL, n (%) 14 (74) 17 (85) 15 (71) 15 (71) NS
Platelets, 109/L
Less than 50, n (%) 10 (53) 11 (58) 7 (33) 5 (24)
More than or equal to 50, n (%) 9 (47) 8 (42) 14 (67) 16 (76) .10
Hemoglobin F
Normal for age, n (%) 6 (55) 3 (20) 6 (40) 4 (33)
Elevated for age, n (%) 5 (45) 12 (80) 9 (60) 8 (67) NS
Unknown, n 8 5 7 9
Bone marrow cytogenetics
Normal, n (%) 15 (94) 11 (65) 15 (75) 12 (60)
Monosomy 7, n (%) 0 (0) 3 (18) 3 (15) 4 (20) NS
Other, n (%) 1 (6) 3 (18) 2 (10) 4 (20)
Unknown, n 3 4 2 1
Liver size
Normal, n (%) 2 (12) 5 (29) 2 (11) 5 (24)
Moderate (1-3 cm), n (%) 2 (12) 4 (24) 6 (33) 10 (48)
Massive ( 4 cm), n (%) 13 (77) 8 (47) 10 (56) 6 (29) .09
Unknown, n 2 3 4 0
Spleen size
Normal, n (%) 0 (0) 1 (6) 0 (0) 4 (19)
Moderate (1-5 cm), n (%) 4 (27) 9 (53) 8 (42) 10 (48)
Massive ( 6 cm), n (%) 11 (73) 7 (41) 11 (58) 7 (33) .07
Unknown, n 4 3 3 0
Clinical status
Alive, n (%) 11 (58) 15 (79) 12 (55) 15 (71)
Dead, n (%) 8 (42) 4 (21) 9 (43) 6 (29) NS
Unknown, n 0 1 1 0
NS indicates not significant.
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